Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Breast Cancer Reports
Erschienen in: Current Breast Cancer Reports 1/2013

01.03.2013 | Systemic Therapy (J Cortes, Section Editor)

The Role of Liposomal Anthracyclines in Metastatic Breast Cancer

verfasst von: Alessandra Gennari, Marco Piccininno, Samanta Sarti

Erschienen in: Current Breast Cancer Reports | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Anthracyclines (doxorubicin and epirubicin) have traditionally occupied a central place in the treatment of early and advanced breast cancer. In patients with metastatic breast cancer (MBC), anthracycline containing regimens have been shown to be superior in terms of activity and efficacy to non antharcycline containing regimens. However, the incidence of cardiac toxicity related to conventional anthracycline use prevents their administration especially in advanced disease, where higher cumulative doses are needed due to the wide use of these agents in the adjuvant setting. In more recent years, new liposomal formulations of doxorubicin, mainly non pegylated doxorubicin (NPLD) and pegylated doxorubicin (PLD), were developed and are now available for clinical use in MBC. Both agents showed a level of activity and efficacy similar to conventional anthracyclines in head to head comparisons, with an improved cardiac safety profile. This peculiarity also led to the development of very active and safe combinations with trastuzumab in HER-2 positive disease, opening new treatment scenarios in this setting. This review summarizes available evidence on the use of liposomal anthracyclines in advanced breast cancer, including HER-2 positive disease.
Literatur
1.
Lord S, Ghersi D, Gattellari M, et al. Antitumour antibiotic containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2004.
2.
•• Airoldi M, Amadori D, Barni S, et al. Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. Tumori. 2011;97:690–2. This is a comprehensive review on NPLD use in MBC with a focus on cardiac safety.
3.
Piccart-Gebhart MJ, Burzykowski T, Buyse M, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008;26:1980–6.PubMedCrossRef
4.
Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39–51.PubMedCrossRef
5.
Mayer L, Nohria A, Miller K, Rugo H, Carey L, Ryabin N, et al. Cardiovascular safety of adjuvant bevacizumab for breast cancer. Proc Am Soc Clin Oncol. 2010;Abstract 571.
6.
Martin F, Boulikas T. The challenge of liposomes in gene therapy. Gene Ther Mol Biol. 1998;1:173–214.
7.
Harris L, Batist G, Belt R, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002;94:25–36.PubMedCrossRef
8.
Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19:1444–54.PubMed
9.
Batist G, Harris L, Azarnia N, et al. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anticancer Drugs. 2006;17:587–95.PubMedCrossRef
10.
Chan S, Davidson N, Juozaityte E, et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol. 2004;15:1527–34.PubMedCrossRef
11.
•• Van Dalen EC, Michiels EM, Caron HN, et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2006;4:CD005006. Update in: Cochrane Database Syst Rev. 2010. This is a review on the differential cardiotoxic profile of conventional anthracyclines and liposomal formulations.
12.
Nabholtz J-M, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003;21:968–75.PubMedCrossRef
13.
Luck HJ, Thomssen C, Untch M, et al. Multicentric phase II study in first-line treatment of advanced metastatic breast cancer (ABC). Epirubicin/Paclitaxel (ET) vs Epirubicin/Cyclophosphamide (EC). A study of the Ago Breast Cancer Group. Proc Am Soc Clin Oncol. 2000; Abstract 280.
14.
Bonneterre J, Dieras V, Tubiana-Hulin M, et al. Phase II multicenter randomized study of docetaxel plus epirubicin vs 5-Fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer. 2004;91:1466–71.PubMed
15.
Bontenbal M, Braun JJ, Creemers GJ, et al. Phase II to III study comparing doxorubicin and docetaxel with 5-Fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol. 2005;23:7081.PubMedCrossRef
16.
Biganzoli L, Cufer T, Bruning P. Doxorubicin and paclitaxel vs doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: EORTC 10961. J Clin Oncol. 2002;20:3114–21.PubMedCrossRef
17.
Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel vs Fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol. 2001;19:1707–15.PubMed
18.
Schmid J, Krocker R, Kreienberg P, et al. Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial. Cancer Chemother Pharmacol. 2009;64:401–6.PubMedCrossRef
19.
Rosati M, Raimondi C, Baciarello G, et al. Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALt trial (phase I–II). Ann Oncol. 2011;22:315–20.PubMedCrossRef
20.
Curtit E, Nouyrigat P, Dohollou N, et al. Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. Eur J Cancer. 2011;47:2396–402.PubMedCrossRef
21.
Theodoulou M, Batist G, Campos S, et al. Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer. Clin Breast Cancer. 2009;9:101–7.PubMedCrossRef
22.
• Cortes J, Di Cosimo S, Climent MA, et al. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study. Clin Cancer Res. 2009;15:307–14. This is a phase II trial on the combination of NPLD and trastuzumab, showing the feasibility and antitumor efficacy in advanced breast cancer.
23.
Venturini M, Bighin C, Puglisi F, et al. A multicenter Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer. Breast. 2010;19:333–8.PubMedCrossRef
24.
Amadori D, Milandri C, Comella G, et al. A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel, and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer. Eur J Cancer. 2011;47:2091–8.PubMedCrossRef
25.
Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol. 1996;36:55–63.PubMed
26.
O'Brien ME, Wigler N, Inbar M, et al. CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) vs conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440–9.PubMedCrossRef
27.
Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, et al. Randomized phase III trial of pegylated liposomal doxorubicin vs vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol. 2004;22:3893–901.PubMedCrossRef
28.
Coleman RE, Biganzoli L, Canney P, Dirix L, Mauriac L, Chollet P, et al. A randomized phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer. 2006;42:882–7.PubMedCrossRef
29.
Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol. 2007;18:1159–64.PubMedCrossRef
30.
Vorobiof DA, Rapoport BL, Chasen MR, et al. First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicenter phase II study. Breast. 2004;13:219–26.PubMedCrossRef
31.
Alexopoulos A, Karamouzis MV, Stavrinides H, et al. Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer. Ann Oncol. 2004;15:440–9.CrossRef
32.
Rivera E, Valero V, Arun B, et al. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol. 2003;21:3249–54.PubMedCrossRef
33.
Fabi A, Ferretti G, Papaldo P. Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naive and anthracycline pretreated metastatic breast cancer patients. Cancer Chemother Pharmacol. 2006;57:615–23.PubMedCrossRef
34.
Sparano JA, Malik U, Rajdev L, et al. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J Clin Oncol. 2001;19:3117–25.PubMed
35.
Morabito A, Gattuso D, Stani SC, et al. Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer. Breast Cancer Res Treat. 2004;86:249–57.PubMedCrossRef
36.
Jones V, Finucane D, Rodriguez R, et al. Phase II study of weekly paclitaxel (Taxol) and liposomal doxorubicin (Doxil) in patients with locally advanced and metastatic breast cancer. Proc Am Soc Clin Oncol. 2000;21:113a:Abstract 451.
37.
Chia S, Clemons M, Martin LA, et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol. 2006;24:2773–8.PubMedCrossRef
38.
Andreopoulou E, Gaiotti D, Kim E, et al. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2007;7:690–6.PubMedCrossRef
39.
Christodoulou C, Kostopoulos I, Kalofonos HP, et al. Study of the Hellenic Cooperative Oncology Group. Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. Phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Oncology. 2009;76(4):275–85.PubMedCrossRef
40.
Stickeler AE, Maximilian K, Watermann D, et al. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial. Breast Cancer Res Treat. 2009;117:591–8.PubMedCrossRef
41.
Martín M, Sánchez-Rovira P, Muñoz M, et al. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004–2005 study. Ann Oncol. 2011;22:2591–6.PubMedCrossRef
42.
Rochlitz C, Ruhstaller T, Lerch S, et al. Combination of bevacizumab and 2 - weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Ann Oncol. 2011;22:80–5.PubMedCrossRef
43.
Morabito A, Piccirillo MC, Monaco K, et al. First-line chemotherapy for HER-negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment. Oncologist. 2007;12:1288–98.PubMedCrossRef
44.
Kardinal CG, Perry MC, Korzun AH, et al. Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB Study 8081. Cancer. 1988;61:415–9.PubMedCrossRef
45.
Venturini M, Bruzzi P, Del Mastro L, et al. Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer. J Clin Oncol. 1996;14:764–73.PubMed
46.
Pierga JY, Robain M, Jouve M, et al. Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients. Ann Oncol. 2001;12:231–7.PubMedCrossRef
47.
Gennari A, Bruzzi P, Orlandini C, et al. Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy. Br J Cancer. 2004;90:962–7.PubMedCrossRef
48.
Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–7.
49.
Praga C, Beretta G, Vigo PL, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep. 1979;63:827–34.PubMed
50.
Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987;82:1109–18.PubMedCrossRef
51.
Hortobágyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs. 1997;54 Suppl 4:1–7.PubMedCrossRef
52.
Al-Batran SE, Guntner M, Pauglik C, et al. Antrhacyclines rechallenge using pegylate liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials. Br J Cancer. 2010;103:1518–23.PubMedCrossRef
53.
Al-Batran SE, Bischoff J, von Minckwitz G, et al. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicenter phase II trial. Br J Cancer. 2006;94:1615–20.PubMed
54.
Al-Batran SE, Meerpohl HG, von Minckwitz G, Atmaca A, Kleeberg U, Harbeck N, et al. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology. 2006;70:141–6.PubMedCrossRef
55.
Safra F, Muggia S, Jeffers S, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/ m2. Ann Oncol. 2000;11:1029–33.PubMedCrossRef
56.
• Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol. 2011;29:2144–9. This paper demonstrates a benefit in overall survival with prolonged first line chemotherapy administration.
57.
Alba E, Ruiz-Borrego M, Margelí M, et al. Maintenance treatment with pegylated liposomal doxorubicin vs observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001–01 study. Breast Cancer Res Treat. 2010;122:169–76.PubMedCrossRef
Metadaten
Titel
The Role of Liposomal Anthracyclines in Metastatic Breast Cancer
verfasst von
Alessandra Gennari
Marco Piccininno
Samanta Sarti
Publikationsdatum
01.03.2013
Verlag
Current Science Inc.
Erschienen in
Current Breast Cancer Reports / Ausgabe 1/2013
Print ISSN: 1943-4588
Elektronische ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-012-0099-z

Weitere Artikel der Ausgabe 1/2013

Current Breast Cancer Reports 1/2013 Zur Ausgabe

Systemic Therapy (J Cortes, Section Editor)

New Microtubule Inhibitors in Breast Cancer

Systemic Therapy (J Cortes, Section Editor)

Update on the Role of Epothilones in Metastatic Breast Cancer

Systemic Therapy (J Cortes, Section Editor)

The Role of Platinum Compounds for the Treatment of Breast Cancer

Systemic Therapy (J Cortes, Section Editor)

Chemotherapy in Patients with Anthracycline and Taxane-Pretreated Metastatic Breast Cancer: An Overview

Systemic Therapy (J Cortes, Section Editor)

The Future of Chemotherapy in the Era of Personalized Medicine

Systemic Therapy (J Cortes, Section Editor)

Topoisomerase Inhibitors in Metastatic Breast Cancer: Overview of Current Practice and Future Development

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise